Study of polymorphisms of UGT1A1 and DPYD genes in chemotherapy for colorectal cancer

Background. The personalized approach implies an individual choice of medicines and their doses for the patient, providing the most effective and safe pharmacotherapy. Objective: analysis of the frequencies of UGT1A1 and DPYD polymorphisms and comparison of genotyping data with irinotecan and 5-fluorouracil-induced toxicity, respectively.

Materials and Methods. Venous blood of 94 Caucasian patients (46 men and 48 women, median age 61 years). The *6 and *28 UGT1A1 alleles were identified by pyrosequencing, and the *2А DPYD allele was identified by Real-time PCR.

Results. The genotyping of 94 patients with colon cancer did not reveal the *2A SNP in the DPYD gene. The frequency rate of the *6 and *28 alleles of the UGT1A1 gene was 0.346 and 0.016, respectively. 24 % of patients receiving chemotherapy with 5-fluorouracil developed side effects associated with the circulatory system and the gastrointestinal tract. Hematological and nonhematological toxic reactions were noted in 48 % and 50 % of patients receiving irinotecan. Severe bilirubinemia was associated with the *28/*28 UGT1A1 genotype. The presence of a high-risk genotype (*28/*1, *28/*28 UGT1A1) correlated with the development of side effects (p=0.040).

Conclusion. The absence of carriers of the *2А DPYD allele in the sample with a significant proportion of pronounced adverse toxic reactions to 5-fluorouracil causes the need for the inclusion of new polymorphisms of the DPYD gene in pharmacogenetic testing. The inclusion of genotyping of UGT1A1 polymorphisms into a complex of preliminary examination is advisable when planning treatment with irinotecan.

1. Caudle K.E., Klein T.E., MullerDJ., Hoffman J.M., Whirl-CarrilloM., Gong L., McDonagh E.M., Sangkuhl K., Thorn C.F., Schwab M., Agun-dezJA.G.,FreimuthR.R.,Huser V,LeeM.T.M.,IwuchukwuO.F., CrewsL.R., Scott S.A., Wadelius M., Swen J.J., Tyndale R.F., Stein C.M., Roden D., Relling M.V, Williams M.S., Johnson S.G. Incorporation of Pharmacog-enomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism. 2014; 15 (2): 209-217. doi: 10.2174/1389200215666140130124910.

2. Swen J.J., Nijenhuis M., de Boer A., Grandia L., Maitland-van der Zee A.H., Mulder H., Rongen G.A., van Schaik R.H., Schalekamp T., Touw D.J., van der Weide J., Wilffert B., Deneer VH., Guchelaar HJ. Pharmacogenetics: from bench to byte an update of guidelines. Clin Pharmacol Ther. 2011 May; 89 (5): 662-73. doi: 10.1038/clpt.2011.34.

3. WilsonP.M., DanenbergP. V, JohnstonPG., LenzHJ., LadnerR.D. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014 May; 11 (5): 282-98. doi: 10.1038/nrclinonc.2014.51.

4. Xu Q., Ding Y.Y., Song LX., Xu J.F. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer. Genetics and molecular research. 29 Jun 2015, 14 (2): 7241-7. doi: 10.4238/2015.June.29.17.

5. Переводчикова Н.И., Горбунова Н.А. Руководство по химиотерапии опухолевых заболеваний. М., 2015. 688. [Perevod-chikova N.I., Gorbunova N.A. Guidelines for the chemotherapy of tumor diseases. Moscow, 2015. 688. (in Russian)].

6. Fukuda M., Suetsugu T., Shimada M., Kitazaki T., Hashiguchi K., Kishimoto J., Harada T., Seto T., EbiN., TakayamaK., SugioK., SembaH., Nakanishi Y., Ichinose Y. Prospective study of the UGT1A1*27gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). Thorac Cancer. 2016 Jul; 7 (4): 467-72. doi: 10.1111/1759-7714.12360.

7. Offer SM., Fossum C.C., WegnerN.J., StuflesserAJ., ButterfieldG.L., Diasio R.B. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014 May 1; 74 (9): 2545-54. doi: 10.1158/0008-5472.CAN-13-2482.

8. Terrazzino S., Cargnin S., Del Re M., Danesi R., Canonico P.L., GenazzaniA.A. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Phar-macogenomics. 2013 Aug; 14 (11): 1255-72. doi: 10.2217/pgs.13.116.

9. Ha V.H., Jupp J., Tsang R.Y. Oncology Drug Dosing in Gilbert Syndrome Associated with UGT1A1: A Summary of the Literature. Pharmacotherapy. 2017 Aug; 37 (8): 956-72. doi: 10.1002/phar.1946.

10. Maeda H., Hazam a S., Abdiev S., Okamoto K., Oba K., Sakamoto J., Takahashi K., OkaM., Nakamura D., Tsunedomi R., Okayama N., Mishi-ma H., Kobayashi M. Differencesin UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations. Mol Diagn Ther. 2014 Jun; 18 (3): 333^2. doi: 10.1007/s40291-014-0083-6.

11. KweekelD.M., Gelderblom H., Van der Straaten T., Antonini N.F., Punt C.J., Guchelaar H.J.; Dutch Colorectal Cancer Group study. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer. 2008 Jul 22; 99 (2): 275-82. doi: 10.1038/sj.bjc.6604461.

12. Caudle K.E., Thorn C.F., Klein T.E., Swen J.J., McLeod H.L., Diasio R.B., Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013 Dec; 94 (6): 640-5. doi: 10.1038/clpt.2013.172.

13. SaifM.W., Ezzeldin H., Vance K., Sellers S., Sellers S., Diasio R.B. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol. 2007 Sep; 60 (4): 503-7. doi: 10.1007/s00280-006-0392-5.

14. Yen-Revollo J.L., Van Booven D.J., Peters E.J., Hoskins JM., Engen R.M., Kannall H.D., Ofori-Adjei D., McLeodH.L., Marsh S. Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J. 2009 Dec; 9 (6): 373-9. doi: 10.1038/tpj.2009.28.

15. Etienne-Grimaldi M.C., Boyer J.C., Beroud C., Mbatchi L., van Kuilenburg A., Bobin-Dubigeon C., Thomas F., Chatelut E., Merlin J.L., Pinguet F., Ferrand C.,Meijer J., EvrardA., Llorca L., Romieu G., Follana P, Bachelot T., Chaigneau L., PivotX., Dieras V, LargillierR., MousseauM., Goncalves A., Roche H., Bonneterre J., Servent V, Dohollou N., Chateau Y, Chamorey E., Desvignes J.P., SalgadoD., Ferrero J.M., Milano G. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS One. 2017 May 8; 12 (5): e0175998. doi: 10.1371/journal.pone.0175998.

16. ObradovicM., Mrhar A., Kos M. Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics. 2008 May; 9 (5): 539-49. doi: 10.2217/14622416.9.5.539.

17. Chen Y.J., Hu F., Li C.Y, Fang J.M., Chu L., Zhang X., Chu L., Zhang X., Xu Q. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers. 2014 Feb; 19 (1): 56-62. doi: 10.3109/1354750X.2013.867534.

18. Liu X.H., Lu J., Duan W., Dai Z.M., WangM., Lin S., Yang P.T., Tian T., Liu K., Zhu Y Y, Zheng Y., Sheng Q.W., Dai Z.J. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy. J Cancer. 2017 Feb 25; 8 (4): 691-703. doi: 10.7150/jca.17210.

19. Liu X., Cheng D., Kuang Q., Liu G., Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2014 Apr; 14 (2): 120-9. doi: 10.1038/tpj.2013.10.

20. Ferraldeschi R., MinchellLJ., Roberts S.A., Tobi S., HadfieldK.D., Blackhall F.H., Hadfield K.D., Blackhall F.H., Mullamitha S., Wilson G., Valle J., Saunders M., Newman WG. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009 May; 10 (5): 733-9. doi: 10.2217/pgs.09.20.

21. HirataK., NagataN., Kato T., Okuyama Y., AndohH., TakahashiK., Andoh H., Takahashi K., Oba K., Sakamoto J., Hazama S., Mishima H. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study. Anticancer Res. 2014 Jan; 34 (1): 195-201.

22. Kit O.I., Vladimirova L.Yu., Vodolazhsky D.I., Abramova N.A., Dvadnenko K.V. The role of assessment UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity during chemotherapy for colorectal cancer. Problems in Oncology. 2015; 61 (2): 266-69. (in Russian).

23. Vodolazhsky D.I., Dvadnenko K.V., Timoshkina N.N., Abramova N.A., Maksimov A.Yu., Vladimirova L.Yu. Polymorphism of UGT1A1 gene in patients with colorectal cancer of the south of Russia: results of pilot research. Molecular medicine. 2017; 15 (1): 61-4. (in Russain).